ArticleThe American journal of gastroenterology2025
Can Symptoms and Medical History Predict Outcomes for Hydrogen and Methane Breath Testing?
Article in The American journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHydrogen and methane breath testing (HMBT) is used to diagnose small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO). There are limited data on whether symptoms and medical history can predict outcomes on lactulose HMBT.
methodsA large survey-based study was conducted in 731 patients who completed lactulose HMBT at a single tertiary center in the United Kingdom. The 32-item survey included questions relating to symptoms and medical history. Survey items were statistically interrogated to determine associations with SIBO, IMO, or breath gas production using Fisher exact tests and regression models. SIBO was determined by a rise of ≥20 ppm in breath hydrogen from baseline within 90 minutes and IMO by the presence of ≥10 ppm methane in any breath sample.
resultsAbdominal pain ( P = 0.022), excessive belching ( P = 0.041), and regurgitation ( P = 0.034) were associated with SIBO, as well as daily abdominal pain with diarrhea ( P = 0.035), and abdominal pain or discomfort immediately after eating (odds ratio 2.20, 95% CI 1.29-3.79). Patients reporting at least 1 skin condition were more likely to test positive for SIBO, with a trend toward significance for eczema ( P = 0.051) and rosacea ( P = 0.067). IMO was associated with constipation ( P < 0.001) and with fatty/greasy stools that tend to float ( P < 0.001). DISCUSSION: This large questionnaire study demonstrated that irritable bowel syndrome-like symptoms, refractory gastroesophageal reflux symptoms, and skin conditions are associated with outcomes on HMBT. These findings support the use of HMBT in accordance with current clinical guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.